JP2021527407A5 - - Google Patents
Info
- Publication number
- JP2021527407A5 JP2021527407A5 JP2020569166A JP2020569166A JP2021527407A5 JP 2021527407 A5 JP2021527407 A5 JP 2021527407A5 JP 2020569166 A JP2020569166 A JP 2020569166A JP 2020569166 A JP2020569166 A JP 2020569166A JP 2021527407 A5 JP2021527407 A5 JP 2021527407A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- amyloidosis
- amyloid
- seq
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862685757P | 2018-06-15 | 2018-06-15 | |
| US62/685,757 | 2018-06-15 | ||
| US201862749499P | 2018-10-23 | 2018-10-23 | |
| US62/749,499 | 2018-10-23 | ||
| PCT/US2019/037179 WO2019241628A1 (en) | 2018-06-15 | 2019-06-14 | General amyloid interaction motif (gaim) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021527407A JP2021527407A (ja) | 2021-10-14 |
| JP2021527407A5 true JP2021527407A5 (enExample) | 2022-06-01 |
| JP7549536B2 JP7549536B2 (ja) | 2024-09-11 |
Family
ID=67263052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020569166A Active JP7549536B2 (ja) | 2018-06-15 | 2019-06-14 | 全般的アミロイド相互作用モチーフ（ｇａｉｍ） |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11692017B2 (enExample) |
| EP (2) | EP3806884B1 (enExample) |
| JP (1) | JP7549536B2 (enExample) |
| CN (1) | CN112672755A (enExample) |
| AU (1) | AU2019287623B2 (enExample) |
| BR (1) | BR112020025111A2 (enExample) |
| ES (1) | ES2960493T3 (enExample) |
| IL (1) | IL279333B2 (enExample) |
| MX (1) | MX2020013525A (enExample) |
| PL (1) | PL3806884T3 (enExample) |
| SG (1) | SG11202012091WA (enExample) |
| WO (1) | WO2019241628A1 (enExample) |
| ZA (1) | ZA202100071B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3806884B1 (en) * | 2018-06-15 | 2023-08-02 | Amyl Therapeutics | General amyloid interaction motif (gaim) |
| JP7505713B2 (ja) | 2019-02-22 | 2024-06-25 | ロヨラ メリーマウント ユニバーシティ | アミロイドペプチドバリアント |
| CN120641092A (zh) | 2022-12-02 | 2025-09-12 | 阿尔泽恩股份有限公司 | 用于用曲米沙特治疗神经变性病症的方法 |
| CN117343200B (zh) * | 2023-12-04 | 2024-01-30 | 北京质肽生物医药科技有限公司 | 一种包含淀粉样核心多肽的融合蛋白、制备方法及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
| US4215051A (en) | 1979-08-29 | 1980-07-29 | Standard Oil Company (Indiana) | Formation, purification and recovery of phthalic anhydride |
| CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| US8022270B2 (en) | 2000-07-31 | 2011-09-20 | Biolex Therapeutics, Inc. | Expression of biologically active polypeptides in duckweed |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP1673395A1 (en) | 2003-10-15 | 2006-06-28 | PDL BioPharma, Inc. | Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig |
| US9493515B2 (en) * | 2011-11-29 | 2016-11-15 | Proclara Biosciences, Inc. | Bacteriophage gene 3 protein compositions and use as amyloid binding agents |
| EA033666B1 (ru) * | 2012-10-02 | 2019-11-14 | Proclara Biosciences Inc | Амилоидсвязывающие белки и их применение |
| JP2016526044A (ja) * | 2013-05-28 | 2016-09-01 | ニューロファージ ファーマシューティカルズ， インコーポレイテッド | 低減された免疫原性を有する修飾されたバクテリオファージｇ３ｐアミノ酸配列を含むポリペプチド |
| KR20170085132A (ko) | 2014-12-03 | 2017-07-21 | 프로클라라 바이오사이언시즈, 인크. | 글리코실화 신호가 결핍된 변형된 박테리오파지 ｇ3ｐ 아미노산 서열을 포함하는 폴리펩티드 |
| EP3806884B1 (en) * | 2018-06-15 | 2023-08-02 | Amyl Therapeutics | General amyloid interaction motif (gaim) |
-
2019
- 2019-06-14 EP EP19739769.8A patent/EP3806884B1/en active Active
- 2019-06-14 WO PCT/US2019/037179 patent/WO2019241628A1/en not_active Ceased
- 2019-06-14 MX MX2020013525A patent/MX2020013525A/es unknown
- 2019-06-14 ES ES19739769T patent/ES2960493T3/es active Active
- 2019-06-14 EP EP23188404.0A patent/EP4389154A3/en active Pending
- 2019-06-14 CN CN201980049538.2A patent/CN112672755A/zh active Pending
- 2019-06-14 AU AU2019287623A patent/AU2019287623B2/en active Active
- 2019-06-14 US US17/251,351 patent/US11692017B2/en active Active
- 2019-06-14 PL PL19739769.8T patent/PL3806884T3/pl unknown
- 2019-06-14 SG SG11202012091WA patent/SG11202012091WA/en unknown
- 2019-06-14 JP JP2020569166A patent/JP7549536B2/ja active Active
- 2019-06-14 BR BR112020025111-9A patent/BR112020025111A2/pt unknown
-
2020
- 2020-12-09 IL IL279333A patent/IL279333B2/en unknown
-
2021
- 2021-01-05 ZA ZA2021/00071A patent/ZA202100071B/en unknown
-
2023
- 2023-05-19 US US18/320,697 patent/US12247055B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Žerovnik | Amyloid-fibril formation: proposed mechanisms and relevance to conformational disease | |
| CN102131519B (zh) | 诊断抗体测定 | |
| US20240000971A1 (en) | Compositions and methods for the treatment of tauopathy | |
| Sidhu et al. | Distinct mechanisms determine α-synuclein fibril morphology during growth and maturation | |
| JP6283366B2 (ja) | アミロイド結合剤としてのバクテリオファージ融合タンパク質のｐ３の使用 | |
| JP2012530055A5 (enExample) | ||
| IL116416A (en) | Molecules and preparations to prevent the formation of accumulations of proteins | |
| Nerelius et al. | Anti-amyloid activity of the C-terminal domain of proSP-C against amyloid β-peptide and medin | |
| Vidal et al. | Cerebral amyloid angiopathy and parenchymal amyloid deposition in transgenic mice expressing the Danish mutant form of human BRI2 | |
| US12247055B2 (en) | General amyloid interaction motif (GAIM) | |
| JP2020511976A (ja) | タウに特異的に結合する結合分子 | |
| JP2017538407A5 (enExample) | ||
| JP2017122124A (ja) | アミロイド結合剤としてのバクテリオファージのｐ３の使用 | |
| Lu et al. | Expression and structural characterization of the recombinant human doppel protein | |
| JP2015505823A5 (enExample) | ||
| Maeda et al. | Tau oligomers | |
| JP2016526044A5 (enExample) | ||
| Choi et al. | Generation of monoclonal antibody recognized by the GXXXG motif (glycine zipper) of prion protein | |
| Arawaka et al. | Heat shock proteins as suppressors of accumulation of toxic prefibrillar intermediates and misfolded proteins in neurodegenerative diseases | |
| Golenhofen et al. | The impact of small heat shock proteins (HspBs) in Alzheimer’s and other neurological diseases | |
| Yuan et al. | Accessibility of a critical prion protein region involved in strain recognition and its implications for the early detection of prions | |
| Messer et al. | Developing intrabodies for the therapeutic suppression of neurodegenerative pathology | |
| LeVatte et al. | Preparation and characterization of a highly soluble Aβ1-42 peptide variant | |
| Pham et al. | Normal cellular prion protein with a methionine at position 129 has a more exposed helix 1 and is more prone to aggregate | |
| Eva | Amyloid‐fibril formation: Proposed mechanisms and relevance to conformational disease |